The insulin-like growth factor system in human immunodeficiency virus infection: Relations to immunological parameters, disease progression, and antiretroviral therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 1, 2001, Pages 227-233

  Helle, S I ^a   Ueland, T ^b   Ekse, D ^a   Froland S S ^b   Holly, J M P ^c   Lonning P E ^a   Aukrust, P ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RECOMBINANT SOMATOMEDIN B; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN A; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNOLOGICAL PARAMETERS; INSULIN RESISTANCE; LEUKOCYTE COUNT; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD; WASTING SYNDROME;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROVIRIDAE; SOMATOMEDINS; WASTING SYNDROME;

EID: 0035145813     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.1.227     Document Type: Article

References (42)

1. Pathogenesis of human immunodeficiency virus infection
2. Pathogenesis of AIDS lymphoma
3. Kaposi's sarcoma and cloacogenic carcinoma associated with AIDS
4. The immunopathogenesis of human immunodeficiency virus infection
5. The macrophage in persistence and pathogenesis of HIV infection
6. Decreased bone formation and enhanced resorptive markers in human immunodeficiency virus infection: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy
7. Endocrinological complications of HIV infection
8. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
9. Proteolysis of insulin-like growth factor-binding protein-3 in human immunodeficiency virus-positive children who fail to thrive
10. Wasting in the aquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system
11. Insulin-like growth factors and their binding proteins: Biological actions
12. Role of insulin-like growth factor binding proteins in controlling IGF actions
13. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma
14. Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: Effects of a pregnancy associated serum protease activity
15. The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1,2 and 3 after elective abdominal surgery
16. The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery
17. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness
18. Effects of treatment with megestrol acetate, aminoglutethimide or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs) and IGFBP-3 protease status in patients with advanced breast cancer
19. Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis
20. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-α production
21. The role of growth hormone and insulin-like growth factor I in the regulation of apoptosis
22. Influence of treatment with tamoxifen and change in tumour burden on the IGF-system in breast cancer patients
23. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin
24. Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids
25. Insulin-like growth factor binding proteins (IGFBPs) in acromegaly
26. Analysis of serum insulin-like growth factor binding proteins using Western ligand blotting: Use of the method of titration of the binding proteins in competitive binding studies
27. Possible role of proinflammatory cytokines in heart allograft coronary artery disease
28. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
29. Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors of acute leukemia
30. Insulin-like growth factor-binding protein-2 and insulin: Studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young
31. Activation-dependent expression of the insulin-like growth factor binding protein-2 in human lymphocytes
32. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: A possible role for insulin in the regulation of IGFBP-3 protease activity
33. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease
34. Insulin-like growth factors (IGFs) and IGF-binding proteins in human interstitial fluid
35. Evidence that limited proteolysis of insulin-like growth factor binding protein-3 (IGFBP-3) occurs in the normal state outside of the bloodstream
36. Alterations in IGF-I:IGF-II, IGFBP-1, IGFBP-3 and IGFBP-3 protease activity during the menstrual cycle in normal women
37. Persistently elevated levels of von Willebrand factor antigen in HIV infection: Downregulation during highly active antiretroviral therapy
38. TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and -independent mechanisms
39. Interleukin-1 and tumor necrosis factor-α increase insulin-like growth factor-binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes
40. Tumor necrosis factor (TNF) system levels in human immunodefidency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure
41. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance
42. Effects of IGFBP-2 overexpression in vitro and in vivo